Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Inhibitor Therapeutics, Inc. (INTI) had Return on Equity of -57.27% for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
-- |
|
$-3.03M |
|
-- |
|
-- |
|
$3.40M |
|
$-3.40M |
|
$0.38M |
|
$-3.03M |
|
$-3.03M |
|
$-3.03M |
|
$-3.03M |
|
$-3.03M |
|
$-3.03M |
|
$-3.40M |
|
$-3.40M |
|
171.95M |
|
171.95M |
|
$-0.02 |
|
$-0.02 |
|
| Balance Sheet Financials | |
$8.95M |
|
-- |
|
-- |
|
$8.95M |
|
$0.67M |
|
-- |
|
$3.00M |
|
$3.67M |
|
$5.28M |
|
$5.28M |
|
$5.28M |
|
172.02M |
|
| Cash Flow Statement Financials | |
$-2.70M |
|
-- |
|
$-0.41M |
|
$11.95M |
|
$8.84M |
|
$-3.11M |
|
$0.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.45 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.70M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-57.27% |
-57.27% |
|
-33.81% |
|
-57.27% |
|
$0.03 |
|
$-0.02 |
|
$-0.02 |
|